NCT06211543View on ClinicalTrials.gov

Letermovir (LMV) Prophylaxis in CMV-seronegative Allogeneic Stem Cell Transplant Recipients With CMV Seropositive Donors: an Exploratory Study From Spanish GETH/TC Centers

Not yet recruitingOBSERVATIONAL
Enrollment

80

Participants

Timeline

Start Date

March 30, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

March 30, 2026

Conditions
CMV
All Listed Sponsors
lead

Grupo Espanol de trasplantes hematopoyeticos y terapia celular

OTHER

NCT06211543 - Letermovir (LMV) Prophylaxis in CMV-seronegative Allogeneic Stem Cell Transplant Recipients With CMV Seropositive Donors: an Exploratory Study From Spanish GETH/TC Centers | Biotech Hunter | Biotech Hunter